Dupuytren’s Disease Market Size, Share & Trends Analysis Report By Type (Diagnosis, Treatment), By Disease Type (Type I, Type II), By End-use (Hospitals, Clinics), By Region (Europe, Asia Pacific), And Segment Forecasts, 2023 - 2030

Report Overview

The global dupuytren’s disease market size was estimated at USD 4.13 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.55% from 2023 to 2030. The projected growth is attributed to the increasing prevalence and advancements in medical research & technology. As the market expands, it presents opportunities for stakeholders to meet the evolving needs of patients and enhance disease management outcomes. The Journal of Hand Surgery emphasizes the significance of developing additional nonsurgical approaches for treating Dupuytren's disorder, fostering ongoing discussions among hand surgeons regarding novel therapies and modalities. This review article explores potential treatment options that aim to mitigate the risks associated with invasive treatments and minimize the likelihood of recurrence, ultimately benefiting both patients and healthcare providers.

The market is experiencing significant growth driven by the increasing prevalence of the disease. A recent study published in the Journal of Hand Surgery revealed a notable rise in diagnosed cases, indicating a growing patient population in need of treatment options. This has resulted in increased investments in research and development by pharmaceutical companies and medical device manufacturers to meet the demand for effective management strategies. In addition, in 2021 population survey in the U.S. found that up to 7% of the population experiences clinical symptoms, with more than one-third of that population being affected by the impact of Dupuytren’s contractures on daily function.

These findings highlight the growing need for accessible and effective treatments. The market holds promising opportunities due to increasing research and development activities and the emergence of new markets. This, combined with the high unmet need for treatments and advancements in healthcare technology, creates a positive market outlook. Notably, the positive results from 180 Therapeutics' Phase 2a clinical trial of anti-TNF therapy in Dupuytren’s disease mark a significant milestone. These results highlight the potential breakthrough in managing the condition and the effectiveness of anti-TNF therapy as a viable approach. This opens avenues for further research, development, and exploration of the therapy, potentially revolutionizing the treatment landscape and addressing the unmet needs of patients.

Stakeholders in the healthcare industry now have an opportunity to contribute to improving treatment options and enhance the overall management of the disease, ultimately leading to better outcomes for patients worldwide. The market is witnessing increased collaborations and partnerships among key players, leading to expanded product portfolios and innovative advancements. For instance, in October 2020, Endo International's acquisition of BioSpecific Technologies Corp. promises to enhance the production and range of treatment options for Dupuytren’s disease. These collaborations enable comprehensive care measures, diagnostic techniques, and diverse treatment options, addressing the unmet needs of patients and driving market growth. Such collaborative efforts are crucial in advancing industry and ultimately benefiting patients globally.

Disease Type Insights

The disease type II segment led the market in 2022 with a revenue share of 62.50%. Type II Dupuytren’s, characterized by involvement of the palmar fascia and digital cords resulting in finger flexion deformities, is projected to be the leading segment in the market. Recent comprehensive research on the worldwide prevalence of the disease highlights that type II represents a substantial proportion of diagnosed cases, emphasizing its higher prevalence and impact.

This dominance underscores the crucial need for effective treatment options and management strategies to address the complexities associated with finger deformities. As a result, pharmaceutical companies and medical device manufacturers are increasingly focusing their efforts on developing innovative therapies and interventions specifically targeting type II Dupuytren’s disorder to meet the growing demands of the patient population.

Type Insights

The treatment segment dominated the market in 2022 with a revenue share of 78.96% and is expected to grow at the fastest CAGR over the forecast period. The dominance is attributed to the increasing focus on developing effective treatment options for managing the disease and improving patients' well-being. Pharmaceutical companies and medical device manufacturers have been actively engaged in research and development activities to introduce innovative treatment approaches. For instance, in June 2023, Endo International Plc announced the enrollment of the first patient for GRASP-DC (Generating Real-world Ambispective Data to Study Participant Treatment Outcomes for Dupuytren's Contracture). It is a registry of 1,000 patients with Dupuytren's disease.

The growth of the market has been fueled by improvements in medical technology and surgical methods, leading to a wide variety of treatment choices. These options include non-invasive therapies and surgical procedures that give healthcare professionals the ability to tailor treatment strategies to the specific needs of each patient. In addition, a growing understanding of the value of early diagnosis and intervention among patients and healthcare professionals can be linked to the domination of the treatment segment. The market is anticipated to rise as a result of industry efforts to meet patient demands, continued research & development, and rising awareness.

End-use Insights

The hospital segment accounted for the largest revenue share of 64.44% in 2022 due to factors, such as the role of hospitals as comprehensive healthcare facilities with specialized care and treatment options. With dedicated departments focused on hand surgery and rehabilitation, hospitals provide holistic care to patients. In addition, hospitals’ advanced infrastructure and state-of-the-art facilities, including specialized operating rooms, enable them to perform intricate procedures, giving them a competitive edge. An example of this dominance is the establishment of specialized Dupuytren’s disease centers within renowned hospitals. These centers cater specifically to patients suffering from this condition, offering centralized support & comprehensive care from diagnosis to treatment and rehabilitation.

The clinics segment is expected to grow at a significant CAGR over the forecast period as clinics offering specialized care for Dupuytren's disease attract patients seeking targeted management with shorter waiting times and flexible scheduling. The easy access to minimally invasive procedures in clinics provides less disruptive options and quicker recovery. The establishment of specialized Dupuytren’s disease clinics in urban areas caters to comprehensive patient needs, driving the growth of the segment and meeting the demand for personalized care and specialized expertise.

Regional Insights

Europe accounted for the largest share of around 41.86% of the overall revenue in 2022. This can be attributed to several key factors, including the higher prevalence of the disease, well-established healthcare systems with advanced infrastructure, and strong research & development initiatives. The active participation of industry players and pharmaceutical companies further strengthens Europe's position by driving innovation and facilitating the introduction of advanced therapies. For instance, the enrollment initiative by 180 Life Sciences for their frozen shoulder treatment trial represents a significant research breakthrough with potential benefits for both Dupuytren’s disease and frozen shoulder patients. Furthermore, the recent approval of Xiapex by Swedish Orphan Biovitrum AB (publ) as a treatment for Dupuytren's contracture and Peyronie's disease solidifies Europe's leadership in addressing the healthcare needs of individuals affected by these conditions.

The Asia Pacific regional market is estimated to grow at the fastest CAGR during the forecast period. The rapid growth of the region can be attributed to the factors, such as increasing awareness, improved healthcare infrastructure, and advancements in treatment options. The rising awareness about the disease in the region has led to improved diagnosis rates and a higher demand for effective therapies & specialized care. Moreover, Asia Pacific has witnessed significant advancements in medical technologies, such as the introduction of collagenase injection therapy, which offers patients a minimally invasive alternative to surgery and has gained popularity in countries like Japan and South Korea.

Key Companies & Market Share Insights

The market is growing significantly due to increasing awareness, treatment advancements, and a growing patient population. This creates opportunities for major players to capitalize on by offering effective therapies and specialized care. Market participants are actively engaging in strategic initiatives like mergers, acquisitions, and collaborations to enhance their industry share and cater to the rising demand for the disease treatment.

For instance, in April 2022, 180 Life Sciences and the University of Oxford announced the publication of positive Phase 2b study results for Dupuytren’s, marking a significant milestone. Another example includes a newly launched specialty pharmaceutical company in April 2023, Ventoux Biosciences, which is dedicated to transforming the management of fibrotic diseases, including Dupuytren’s disease. With a focus on delivering life-changing therapies, the company has commenced pre-clinical evaluation of its early-stage pipeline, VEN-201, and VEN-202. Some prominent players in the global dupuytren’s disease market include:

• Bayer AG

• Novartis AG

• Pfizer Inc.

• Nantong Jinghua Pharmaceutical Co., Ltd.

• Actiza Pharmaceutical Private Limited

• Endo International plc

• Bristol-Meyers Squibb Company

• Spear Pharmaceuticals

• GSK plc

• AstraZeneca

• Hikma Pharmaceuticals PLC

• LEO Pharma A/S

• Fresenius Kabi AG

Dupuytren’s Disease Market Report Scope

Global Dupuytren’s Disease Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Dupuytren’s disease market report based on disease type, type, end-use, and region:

• Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Type I

  • Type II

  • Type III

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Diagnosis

    • Physical Examination

    • X-ray

  • Treatment

    • Surgery

    • Radiation Therapy

    • Needle Aponeurotomy

    • Steroid Shot

    • Enzyme Injection

    • Occupational Therapy

    • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Clinics

  • Academic & Research Institute

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait